Psoriasis Trial, Recruiting (NCT07552454)

Psoriasis Trial, Recruiting NCT07552454 Sponsor: Xijing Hospital Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07552454 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 to 65 years, of any gender
People who have been diagnosed with palmoplantar pustulosis (a skin condition causing pustules on the hands and feet) based on clinical examination and/or skin tissue testing
People who have already tried at least one standard systemic (whole-body) medication for 12 to 24 weeks at the usual dose without adequate results, or who had to stop due to side effects
People whose treating clinician has assessed them as suitable for treatment with the study drug, picankibart
People who are willing to take part and have signed a written consent form

Who may not be able to join:

People who currently have active hepatitis B, hepatitis C, or tuberculosis
People who are pregnant or planning to become pregnant within 6 months
People who would not be able to attend follow-up visits as required by the study
People who have other health conditions that the study team considers would make participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8619249282690

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07552454

Sponsor: Xijing Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Psoriasis

Trial contact: 8619249282690

More information: https://clinicaltrials.gov/study/NCT07552454

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 to 65 years, of any gender
People who have been diagnosed with palmoplantar pustulosis (a skin condition causing pustules on the hands and feet) based on clinical examination and/or skin tissue testing
People who have already tried at least one standard systemic (whole-body) medication for 12 to 24 weeks at the usual dose without adequate results, or who had to stop due to side effects
People whose treating clinician has assessed them as suitable for treatment with the study drug, picankibart
People who are willing to take part and have signed a written consent form

Who may not be able to join:

People who currently have active hepatitis B, hepatitis C, or tuberculosis
People who are pregnant or planning to become pregnant within 6 months
People who would not be able to attend follow-up visits as required by the study
People who have other health conditions that the study team considers would make participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Xijing Hospital

Registry

ClinicalTrials.gov

Start date

15 April 2026

Est. completion

15 October 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI); Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov